Add BrightSurf on Google Email

ASTRO updates guideline on shorter-course radiation therapy for localized prostate cancer

The updated guideline recommends moderate hypofractionation over conventional fractionation for patients across all prostate cancer risk groups who choose EBRT, supported by high-quality randomized data showing comparable outcomes, side effects and quality of life. Ultrahypofractionation is also strongly recommended as a standard optio...

SourceAmerican Society for Radiation Oncology·JournalPractical Radiation Oncology·DateOct 27, 2026

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

A substudy of the PROTEUS regimen found a 62% improvement in event-free survival and a 51% reduced risk of metastasis or death compared to standard of care radical prostatectomy. The combination of apalutamide plus hormone therapy and prostatectomy delayed subsequent therapy by 33 months and reduced the risk of metastases or death by 20%.

SourceDana-Farber Cancer Institute·JournalEuropean Urology·DateOct 26, 2026

Late-breaking: Novel alpha radiopharmaceutical therapy shows promising activity in phase 1 prostate cancer trial

A phase 1 trial of the alpha radiopharmaceutical therapy Pb-ADVC001 showed well-tolerated doses and encouraging signs of antitumor activity in patients with advanced prostate cancer. The therapy's optimized dose schedule and 100% overall response rate suggest potential for improved patient outcomes.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateOct 26, 2026

‘Hiding in plain sight’ - new bacteria discovered in DNA samples from prostate cancer patients

Researchers from the University of East Anglia have discovered 18 new bacterial species collected from prostate cancer patients, including previously linked species like Porphyromonas and Treponema. The study provides new insights into microbes in cancer patients and could uncover links that improve understanding of how cancer develops.

SourceUniversity of East Anglia·Journalnpj Biofilms and Microbiomes·TypeExperimental study·DateOct 19, 2026

Targeted radioactive therapy may help delay spread of recurrent prostate cancer, UCLA study suggests

A new UCLA study suggests that adding a targeted radioactive drug to stereotactic body radiation therapy may help delay the spread of recurrent prostate cancer. The treatment showed a 62% lower risk of progression or needing additional hormone therapy, and improved control of disease on conventional imaging.

Key driver of aggressive prostate cancer identified, suggesting new way to reverse drug resistance

A study published in Nature reveals that a single transfer RNA (tRNA) plays a crucial role in determining prostate cancer's sensitivity to treatment. The study found that a specific tRNA can control the identity of prostate cancer cells and influence their response to therapy, potentially opening new avenues for precision oncology.

SourceFred Hutchinson Cancer Center·JournalNature·TypeExperimental study·DateOct 7, 2026

Chinese Medical Journal study reveals gallic acid inhibits prostate cancer progression via the NF-κB/KLF7/L1CAM Axis

Researchers discovered gallic acid suppresses tumor progression by targeting the NF-κB/KLF7/L1CAM axis in prostate cancer. The study demonstrated that gallic acid significantly impaired aggressive behaviors of PC-3 and LNCaP cells without toxicity to normal cells.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeExperimental study·DateOct 2, 2026

Case report highlights multidisciplinary approach to recurrent prostate cancer

A multidisciplinary approach is crucial for treating recurrent prostate cancer, combining advanced imaging, radiation, and systemic therapies to address microscopic disease. The case report follows Larry Hardesty, who underwent several clinical trials, including PSMA-targeted radioligand therapy, leading to undetectable PSA levels and ...

SourceUniversity of California - Los Angeles Health Sciences·JournalCA A Cancer Journal for Clinicians·DateSep 30, 2026

circLPAR3 drives chemotherapy resistance in prostate cancer

Researchers identified circLPAR3 as a key mediator of docetaxel resistance in prostate cancer, promoting tumor growth under chemotherapy by suppressing ferroptosis. The study highlights circLPAR3 as a promising biomarker for treatment response and suggests targeting its regulatory network could help overcome chemotherapy resistance.

SourceCompuscript Ltd·JournalGenes & Diseases·DateSep 29, 2026

Five-treatment radiation therapy offers effective nonsurgical alternative for localized prostate cancer

A randomized trial found that five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control and better urinary continence and sexual function compared to surgery. SBRT offered clear advantages for urinary continence and sexual function, with 91% of patients remaining free from biochemical or clin...

Shortened radiation schedule provides similar cancer control and patient-reported outcomes to standard radiation following surgery for high-risk prostate cancer in NRG Oncology trial

A new study found that a shortened radiation schedule provides similar cancer control and patient-reported outcomes to standard radiation following surgery for high-risk prostate cancer. However, it was associated with a higher rate of grade 3 urinary adverse events, particularly cystitis and hematuria.

Prostate cancer surgery and radiation have different long-term effects on urinary, sexual, and survival outcomes

A national study of 20,000 men with prostate cancer found that surgery led to higher rates of urinary incontinence and erectile dysfunction, while radiation was associated with urinary complications and higher all-cause mortality. Researchers emphasized that both treatments have long-term consequences and that risks and benefits should...

SourceAmerican College of Surgeons·TypeData/statistical analysis·DateSep 25, 2026

Weill Cornell Medicine fall grants roundup

Weill Cornell Medicine has received significant funding for various cancer research projects, including precision medicine and drug target discovery. These initiatives aim to improve patient outcomes for challenging cancers, such as breast cancer and ovarian cancer. The funding supports innovative research approaches, including the stu...

Researchers uncover dual role of B7-H3 in tumor immune suppression

Researchers identified a previously unknown pathway that prostate tumors leverage to suppress the immune system, reshaping the tumor microenvironment to resist treatment. Combining B7-H3-targeted therapy with MEK inhibition improved antitumor responses and prolonged survival in preclinical models of castration-resistant prostate cancer.

Only 20% of men know consuming dairy products can increase prostate cancer risk, finds new survey

A recent survey found that only 20% of men are aware of the potential prostate cancer risk associated with dairy consumption. The survey also showed that 66% of men plan to avoid dairy products after learning about the risk. A meta-analysis of 32 studies supports the link between high dairy intake and increased prostate cancer risk.

NRG Oncology trial results show favorable bowel health related quality of life outcomes for localized immediate risk prostate cancer treated with stereotactic body radiation therapy – Results published

The NRG-GU005 trial shows that SBRT improves bowel health related quality of life in localized intermediate risk prostate cancer patients, with no significant impact on urinary HRQOL. SBRT is also associated with lower incontinence related quality of life and improved maintenance of erectile dysfunction compared to hypofractionated IMRT.

SourceNRG Oncology·JournalJournal of the American Medical Association·DateAug 25, 2026

Focal therapy for prostate cancer

This retrospective study examines patterns and trends of focal therapy for nonmetastatic prostate cancer in US cancer centers. Focal therapy procedures remained uncommon, occurring mostly in low-, high-, or very-high-risk disease settings.

SourceJAMA Network·JournalJAMA·DateAug 13, 2026

AI tool for computing radiation dose created at UMass Amherst leads the way to personalizing prostate cancer treatment

A team of researchers at UMass Amherst has developed an AI model, DiffuDose, that generates a patient's radiation dose map with gold-standard accuracy in under 23 seconds. This technology has the potential to unlock the full potential of radiopharmaceutical therapy for prostate cancer treatment.

SourceUniversity of Massachusetts Amherst·JournalIEEE Transactions on Radiation and Plasma Medical Sciences·TypeComputational simulation/modeling·DateAug 4, 2026

Combination of targeted therapies could help overcome treatment resistance in advanced prostate cancer

Researchers have identified a promising strategy to improve the effectiveness of targeted therapies in advanced prostate cancer. By combining ADCs with a drug that blocks BCL-XL, they triggered greater cancer cell death and slowed tumor growth. The approach could offer a new strategy for improving antibody-drug conjugates against metas...

SourceUniversity of California - Los Angeles Health Sciences·JournalJournal of Clinical Investigation·DateAug 3, 2026

DNA blood test improves patient selection for radiopharmaceutical therapy in prostate cancer

A noninvasive DNA blood test can identify patients with metastatic castration-resistant prostate cancer most likely to benefit from <sup> 223 </sup> Ra radiopharmaceutical therapy and monitor their progress. The test showed associations between ctDNA profiles and clinical outcomes, including biomarker response and overall survival.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJul 17, 2026

A second look to aim better

The study creates a radiohybrid approach that labels a single molecule with two different diagnostic radionuclides, enabling long-term visualization of therapeutic agent distribution. This allows for personalized cancer medicine by calculating optimal radiation doses for individual patients.

SourceHelmholtz-Zentrum Dresden-Rossendorf·JournalJournal of Medicinal Chemistry·TypeExperimental study·DateJul 14, 2026